Vontobel Holding Ltd. purchased a new stake in shares of OptimizeRx Co. (NASDAQ:OPRX) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 13,075 shares of the company’s stock, valued at approximately $637,000. Vontobel Holding Ltd. owned about 0.08% of OptimizeRx as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Dorsey Wright & Associates raised its holdings in OptimizeRx by 134.2% during the 1st quarter. Dorsey Wright & Associates now owns 1,707 shares of the company’s stock valued at $83,000 after buying an additional 978 shares during the last quarter. Citigroup Inc. increased its position in OptimizeRx by 301.4% during the 4th quarter. Citigroup Inc. now owns 2,806 shares of the company’s stock valued at $87,000 after purchasing an additional 2,107 shares during the period. JPMorgan Chase & Co. increased its position in OptimizeRx by 21.1% during the 4th quarter. JPMorgan Chase & Co. now owns 6,578 shares of the company’s stock valued at $205,000 after purchasing an additional 1,147 shares during the period. Precision Wealth Strategies LLC purchased a new position in OptimizeRx during the 1st quarter valued at $233,000. Finally, Alliancebernstein L.P. purchased a new position in OptimizeRx during the 4th quarter valued at $252,000. Institutional investors own 64.72% of the company’s stock.
A number of research analysts have issued reports on OPRX shares. B. Riley boosted their price objective on shares of OptimizeRx from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, May 7th. Roth Capital boosted their price objective on shares of OptimizeRx from $70.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, February 25th. Royal Bank of Canada began coverage on shares of OptimizeRx in a research report on Monday, April 12th. They issued an “outperform” rating and a $65.00 target price on the stock. Finally, Zacks Investment Research raised shares of OptimizeRx from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Saturday, May 22nd. Five research analysts have rated the stock with a buy rating, OptimizeRx has an average rating of “Buy” and an average price target of $67.80.
NASDAQ:OPRX opened at $51.02 on Friday. The stock has a 50-day simple moving average of $49.34. The stock has a market cap of $881.63 million, a P/E ratio of 1,701.23 and a beta of 0.63. OptimizeRx Co. has a 1-year low of $11.44 and a 1-year high of $63.98.
OptimizeRx Corporation operates as a digital health company that provides communications solutions for life science companies, physicians, and patients. Its products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, therapeutic support messages, and unbranded messages.
Read More: What Is an EV Stock?
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.